STOCK TITAN

Relay Therapeutics Inc - RLAY STOCK NEWS

Welcome to our dedicated news page for Relay Therapeutics (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Relay Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Relay Therapeutics's position in the market.

Rhea-AI Summary
Relay Therapeutics to report Q3 2023 financial results on November 2, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.27%
Tags
-
Rhea-AI Summary
Relay Therapeutics announces initial clinical data for RLY-4008 in patients with FGFR2-altered solid tumors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
conferences clinical trial
Rhea-AI Summary
Relay Therapeutics reports positive interim data for RLY-2608 in breast cancer patients. Clinical benefit rate of 86% and partial response observed. Company has $872 million in cash at end of Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
-
Rhea-AI Summary
Relay Therapeutics, Inc. (Nasdaq: RLAY) to report Q2 2023 financial results and corporate highlights on August 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.95%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.28%
Tags
conferences
Relay Therapeutics Inc

Nasdaq:RLAY

RLAY Rankings

RLAY Stock Data

922.19M
93.01M
3.49%
99.09%
8.52%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About RLAY

relay therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. by placing protein motion at the heart of drug discovery, relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. headquartered in cambridge, mass., relay therapeutics is a private company launched in 2016. to date, relay therapeutics has raised $120m in financing from third rock ventures, bvf partners, gv (formerly google ventures), an affiliate of d.e. shaw research, casdin capital, ecor1 capital, section 32 and alexandria venture investments. our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. if you're creative, collaborative and passionate